Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Pemvidutide: Evidence Summary
Evidence summary for Pemvidutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Pemvidutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| MASH resolution | Tier B | 1 | Phase 2b IMPACT trial showed 59.1% resolution; Phase 3 planned |
| Obesity / weight loss | Tier C | 1 | Phase 2 MOMENTUM trial showed meaningful weight loss |
| Alcohol use disorder | Tier D | 1 | Phase 2 RECLAIM trial recruiting as of 2025 |
References (2)
- Pemvidutide in metabolic dysfunction-associated steatohepatitis: Phase 2b IMPACT trial 24-week results — Altimmune investigators . Hepatology (2025)
- Pemvidutide in adults with obesity: the Phase 2 MOMENTUM trial — Altimmune investigators . Obesity (2024)